Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Blood Draw.
- Кому может быть актуально
- Состояния в реестре: Diagnosis of Cancer of Various Organs. Базовые параметры: 21 лет — 80 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.
Подробное описание
Epigenomic changes in cancer cells can provide a rich source of biomarker signals for the detection of disease. As cancer cells manifest their epigenomic changes in blood due to cell death, DNA and protein molecules can be probed using specific molecular analytic approaches. ClearNote Health employs epigenomic technologies to measure dynamic changes in DNA demethylation events via direct measurement of 5-hydroxymethyl-cytosine residues in cfDNA. Companion assays are also run to provide information on cfDNA digestion patterns and protein-based changes in plasma. This information, combined in a machine learning framework, enable the provision of prediction models that report on the presence of cancer and the determination of the tissue of tumor origin. This study will build predictive models and test performance of these models to detect the presence of cancer and tissue of origin in several cancer type by using a matched case-control study design.
Вмешательства
- Другое Blood Draw
Blood Draw
Первичные конечные точки
- Detection of cancer signal in the cancer cohort [Срок оценки: Baseline]
- Detection of tissue of origin signal in the cancer cohort [Срок оценки: Baseline]
Критерии участия
Критерии включения
- Subjects must be between 21-80 years of age at the time of enrollment
- Patient fully consented
- Cancer diagnosis OR high clinical suspicion for cancer, based on the participating site's and practitioner's standards of care (SOC)
- No previous history of cancer and treatment naïve at time of enrollment
Критерии исключения
- Age < 21 OR > 80 years of age
- Any prior cancer diagnosis with or without treatment (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment)
- Receipt of any cancer therapy including chemotherapy, radiation, palliative radiation, hormonal or naturopathic therapies
- In situ carcinoma without an invasive component
- Any surgery requiring general anesthesia within 2 months of collection. Anesthesia used in procedures such as colonoscopy and EBUS is acceptable.
- Receipt of systemic immunomodulation therapy within past 12 months
- Currently pregnant, or pregnancy within last 12 months
- Organ transplantation
- Received dialysis
- Blood transfusion within 1 month
- Known HIV/AIDs, Hepatitis A, D, or E, TB, any kind of prion disorder (e.g., CJD) or other infectious pathogens currently present or present in past 5 years.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Да
Дизайн исследования
- Модель наблюдения
- Случай-контроль
Центры проведения
США · 1 центр
- ClearNote Health, Inc. — San Diego
Идентификаторы
NCT: NCT03869814 · MT1410